Elevated Urine Levels of Macrophage Migration Inhibitory Factor in Inflammatory Bladder Conditions: A Potential Biomarker for a Subgroup of Interstitial Cystitis/Bladder Pain Syndrome Patients

Pedro L. Vera; David M. Preston; Robert M. Moldwin; Deborah R. Erickson; Behzad Mowlazadeh; Fei Ma; Dimitrios E. Kouzoukas; Katherine L. Meyer-Siegler; Magnus Fall

doi:10.1016/j.urology.2018.02.039

Elevated Urine Levels of Macrophage Migration Inhibitory Factor in Inflammatory Bladder Conditions: A Potential Biomarker for a Subgroup of Interstitial Cystitis/Bladder Pain Syndrome Patients

Pedro L. Vera, David M. Preston, Robert M. Moldwin, Deborah R. Erickson, Behzad Mowlazadeh, Fei Ma, Dimitrios E. Kouzoukas, Katherine L. Meyer-Siegler, Magnus Fall

Urology

Research output: Contribution to journal › Article › peer-review

29 Scopus citations

Abstract

Objective: To investigate whether urinary levels of macrophage migration inhibitory factor (MIF) are elevated in interstitial cystitis/bladder pain syndrome (IC/BPS) patients with Hunner lesions and also whether urine MIF is elevated in other forms of inflammatory cystitis. Methods: Urine samples were assayed for MIF by enzyme-linked immunosorbent assay. Urine samples from 3 female groups were examined: IC/BPS patients without (N = 55) and with Hunner lesions (N = 43), and non-IC/BPS patients (N = 100; control group; no history of IC/BPS; cancer or recent bacterial cystitis). Urine samples from 3 male groups were examined: patients with bacterial cystitis (N = 50), radiation cystitis (N = 18) and noncystitis patients (N = 119; control group; negative for bacterial cystitis). Results: Urine MIF (mean MIF pg/mL ± standard error of the mean) was increased in female IC/BPS patients with Hunner lesions (2159 ± 435.3) compared with IC/BPS patients without Hunner lesions (460 ± 114.5) or non-IC/BPS patients (414 ± 47.6). Receiver operating curve analyses showed that urine MIF levels discriminated between the 2 IC groups (area under the curve = 72%; confidence interval 61%-82%). Male patients with bacterial and radiation cystitis had elevated urine MIF levels (2839 ± 757.1 and 4404 ± 1548.1, respectively) compared with noncystitis patients (681 ± 75.2). Conclusion: Urine MIF is elevated in IC/BPS patients with Hunner lesions and also in patients with other bladder inflammatory and painful conditions. MIF may also serve as a noninvasive biomarker to select IC/BPS patients more accurately for endoscopic evaluation and possible anti-inflammatory treatment.

Original language	English
Pages (from-to)	55-62
Number of pages	8
Journal	Urology
Volume	116
DOIs	https://doi.org/10.1016/j.urology.2018.02.039
State	Published - Jun 2018

Bibliographical note

Publisher Copyright:
© 2018 Elsevier Inc.

Funding

This study was funded by NIH (DK0093496; PLV). We would like to acknowledge grant support from NIH CTSA UL1TR000117. This material is the result of work supported with resources and the use of facilities at the Lexington (Kentucky) Veterans Affairs Medical Center. Judy Glass and Xiu Xu provided excellent technical assistance. Barbara Kahn, MD, provided excellent assistance in the collection of bacterial cystitis and noncystitis samples. This study was funded by NIH ( DK0093496 ; PLV). We would like to acknowledge grant support from NIH CTSA UL1TR000117 . This material is the result of work supported with resources and the use of facilities at the Lexington (Kentucky) Veterans Affairs Medical Center. Judy Glass and Xiu Xu provided excellent technical assistance. Barbara Kahn, MD, provided excellent assistance in the collection of bacterial cystitis and noncystitis samples.

Funders	Funder number
NIH CTSA UL1TR000117	Kentucky
National Institutes of Health (NIH)	DK0093496
National Institutes of Health (NIH)
National Center for Advancing Translational Sciences (NCATS)	UL1TR000117
National Center for Advancing Translational Sciences (NCATS)
Center for Integrated Healthcare, U.S. Department of Veterans Affairs

ASJC Scopus subject areas

Urology

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/j.urology.2018.02.039

Cite this

Vera, P. L., Preston, D. M., Moldwin, R. M., Erickson, D. R., Mowlazadeh, B., Ma, F., Kouzoukas, D. E., Meyer-Siegler, K. L., & Fall, M. (2018). Elevated Urine Levels of Macrophage Migration Inhibitory Factor in Inflammatory Bladder Conditions: A Potential Biomarker for a Subgroup of Interstitial Cystitis/Bladder Pain Syndrome Patients. Urology, 116, 55-62. https://doi.org/10.1016/j.urology.2018.02.039

@article{72735ec1256b4fb8849fb06999ec2649,

title = "Elevated Urine Levels of Macrophage Migration Inhibitory Factor in Inflammatory Bladder Conditions: A Potential Biomarker for a Subgroup of Interstitial Cystitis/Bladder Pain Syndrome Patients",

abstract = "Objective: To investigate whether urinary levels of macrophage migration inhibitory factor (MIF) are elevated in interstitial cystitis/bladder pain syndrome (IC/BPS) patients with Hunner lesions and also whether urine MIF is elevated in other forms of inflammatory cystitis. Methods: Urine samples were assayed for MIF by enzyme-linked immunosorbent assay. Urine samples from 3 female groups were examined: IC/BPS patients without (N = 55) and with Hunner lesions (N = 43), and non-IC/BPS patients (N = 100; control group; no history of IC/BPS; cancer or recent bacterial cystitis). Urine samples from 3 male groups were examined: patients with bacterial cystitis (N = 50), radiation cystitis (N = 18) and noncystitis patients (N = 119; control group; negative for bacterial cystitis). Results: Urine MIF (mean MIF pg/mL ± standard error of the mean) was increased in female IC/BPS patients with Hunner lesions (2159 ± 435.3) compared with IC/BPS patients without Hunner lesions (460 ± 114.5) or non-IC/BPS patients (414 ± 47.6). Receiver operating curve analyses showed that urine MIF levels discriminated between the 2 IC groups (area under the curve = 72\%; confidence interval 61\%-82\%). Male patients with bacterial and radiation cystitis had elevated urine MIF levels (2839 ± 757.1 and 4404 ± 1548.1, respectively) compared with noncystitis patients (681 ± 75.2). Conclusion: Urine MIF is elevated in IC/BPS patients with Hunner lesions and also in patients with other bladder inflammatory and painful conditions. MIF may also serve as a noninvasive biomarker to select IC/BPS patients more accurately for endoscopic evaluation and possible anti-inflammatory treatment.",

author = "Vera, \{Pedro L.\} and Preston, \{David M.\} and Moldwin, \{Robert M.\} and Erickson, \{Deborah R.\} and Behzad Mowlazadeh and Fei Ma and Kouzoukas, \{Dimitrios E.\} and Meyer-Siegler, \{Katherine L.\} and Magnus Fall",

note = "Publisher Copyright: {\textcopyright} 2018 Elsevier Inc.",

year = "2018",

month = jun,

doi = "10.1016/j.urology.2018.02.039",

language = "English",

volume = "116",

pages = "55--62",

}

Vera, PL, Preston, DM, Moldwin, RM, Erickson, DR, Mowlazadeh, B, Ma, F, Kouzoukas, DE, Meyer-Siegler, KL & Fall, M 2018, 'Elevated Urine Levels of Macrophage Migration Inhibitory Factor in Inflammatory Bladder Conditions: A Potential Biomarker for a Subgroup of Interstitial Cystitis/Bladder Pain Syndrome Patients', Urology, vol. 116, pp. 55-62. https://doi.org/10.1016/j.urology.2018.02.039

TY - JOUR

T1 - Elevated Urine Levels of Macrophage Migration Inhibitory Factor in Inflammatory Bladder Conditions

T2 - A Potential Biomarker for a Subgroup of Interstitial Cystitis/Bladder Pain Syndrome Patients

AU - Vera, Pedro L.

AU - Preston, David M.

AU - Moldwin, Robert M.

AU - Erickson, Deborah R.

AU - Mowlazadeh, Behzad

AU - Ma, Fei

AU - Kouzoukas, Dimitrios E.

AU - Meyer-Siegler, Katherine L.

AU - Fall, Magnus

PY - 2018/6

Y1 - 2018/6

N2 - Objective: To investigate whether urinary levels of macrophage migration inhibitory factor (MIF) are elevated in interstitial cystitis/bladder pain syndrome (IC/BPS) patients with Hunner lesions and also whether urine MIF is elevated in other forms of inflammatory cystitis. Methods: Urine samples were assayed for MIF by enzyme-linked immunosorbent assay. Urine samples from 3 female groups were examined: IC/BPS patients without (N = 55) and with Hunner lesions (N = 43), and non-IC/BPS patients (N = 100; control group; no history of IC/BPS; cancer or recent bacterial cystitis). Urine samples from 3 male groups were examined: patients with bacterial cystitis (N = 50), radiation cystitis (N = 18) and noncystitis patients (N = 119; control group; negative for bacterial cystitis). Results: Urine MIF (mean MIF pg/mL ± standard error of the mean) was increased in female IC/BPS patients with Hunner lesions (2159 ± 435.3) compared with IC/BPS patients without Hunner lesions (460 ± 114.5) or non-IC/BPS patients (414 ± 47.6). Receiver operating curve analyses showed that urine MIF levels discriminated between the 2 IC groups (area under the curve = 72%; confidence interval 61%-82%). Male patients with bacterial and radiation cystitis had elevated urine MIF levels (2839 ± 757.1 and 4404 ± 1548.1, respectively) compared with noncystitis patients (681 ± 75.2). Conclusion: Urine MIF is elevated in IC/BPS patients with Hunner lesions and also in patients with other bladder inflammatory and painful conditions. MIF may also serve as a noninvasive biomarker to select IC/BPS patients more accurately for endoscopic evaluation and possible anti-inflammatory treatment.

AB - Objective: To investigate whether urinary levels of macrophage migration inhibitory factor (MIF) are elevated in interstitial cystitis/bladder pain syndrome (IC/BPS) patients with Hunner lesions and also whether urine MIF is elevated in other forms of inflammatory cystitis. Methods: Urine samples were assayed for MIF by enzyme-linked immunosorbent assay. Urine samples from 3 female groups were examined: IC/BPS patients without (N = 55) and with Hunner lesions (N = 43), and non-IC/BPS patients (N = 100; control group; no history of IC/BPS; cancer or recent bacterial cystitis). Urine samples from 3 male groups were examined: patients with bacterial cystitis (N = 50), radiation cystitis (N = 18) and noncystitis patients (N = 119; control group; negative for bacterial cystitis). Results: Urine MIF (mean MIF pg/mL ± standard error of the mean) was increased in female IC/BPS patients with Hunner lesions (2159 ± 435.3) compared with IC/BPS patients without Hunner lesions (460 ± 114.5) or non-IC/BPS patients (414 ± 47.6). Receiver operating curve analyses showed that urine MIF levels discriminated between the 2 IC groups (area under the curve = 72%; confidence interval 61%-82%). Male patients with bacterial and radiation cystitis had elevated urine MIF levels (2839 ± 757.1 and 4404 ± 1548.1, respectively) compared with noncystitis patients (681 ± 75.2). Conclusion: Urine MIF is elevated in IC/BPS patients with Hunner lesions and also in patients with other bladder inflammatory and painful conditions. MIF may also serve as a noninvasive biomarker to select IC/BPS patients more accurately for endoscopic evaluation and possible anti-inflammatory treatment.

UR - https://www.scopus.com/pages/publications/85046154926

UR - https://www.scopus.com/inward/citedby.url?scp=85046154926&partnerID=8YFLogxK

U2 - 10.1016/j.urology.2018.02.039

DO - 10.1016/j.urology.2018.02.039

M3 - Article

C2 - 29580781

AN - SCOPUS:85046154926

SN - 0090-4295

VL - 116

SP - 55

EP - 62

JO - Urology

JF - Urology

ER -

Elevated Urine Levels of Macrophage Migration Inhibitory Factor in Inflammatory Bladder Conditions: A Potential Biomarker for a Subgroup of Interstitial Cystitis/Bladder Pain Syndrome Patients

Abstract

Bibliographical note

Funding

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this